Answers are grounded in this paper and cite their sources.
T-cell immunotherapy is a promising treatment option for cancer. The identification of tumor antigens that are recognized by the immune system has allowed for the generation of vaccines for various malignancies. Due to the ease of manufacturing and characterizating peptide-based vaccines they have been used to stimulate antitumor T-cells. This article will review the use of peptide-based vaccines for the treatment of cancer by inducing antitumor T-lymphocyte responses.
No takes yet. Share an insight, caveat, or question.
Elsawa et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: